Wellgistics Health to Acquire Kare Rx Hub in All-Stock Deal

Reuters
Nov 04
Wellgistics Health to Acquire Kare Rx Hub in All-Stock Deal

Wellgistics Health, Inc. has entered into a non-binding letter of intent to acquire Kare Rx Hub, LLC, an AI-based digital hub for retail pharmacies and telemedicine services, from Kare Pharmtech, LLC. The transaction, expected to close by January 31, 2026, will be completed through an all-stock deal. Upon completion, Wellgistics will gain KareRx's telemedicine offering, which will integrate with Wellgistics Pharmacy to support telemedicine providers nationwide. The deal will also add over 500 physician-provider relationships, more than 200 independent pharmacy partnerships, and three unique manufacturer relationships to Wellgistics' network. KareRx's team of healthcare professionals will join Wellgistics, further strengthening its industry expertise and expanding its reach in the pharmaceutical sector.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wellgistics Health Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 273075) on November 04, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10